An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Biologic License Application (BLA): 761083
Company: GENENTECH INC

Medication Guide

Products on BLA 761083

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
HEMLIBRA	EMICIZUMAB	30MG/ML	INJECTABLE;INJECTION	Prescription	None	TBD	No
HEMLIBRA	EMICIZUMAB	60MG/0.4ML	INJECTABLE;INJECTION	Prescription	None	TBD	No
HEMLIBRA	EMICIZUMAB	105MG/0.7ML	INJECTABLE;INJECTION	Prescription	None	TBD	No
HEMLIBRA	EMICIZUMAB	150MG	INJECTABLE;INJECTION	Prescription	None	TBD	No

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761083

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
11/16/2017	ORIG-1	Approval		N/A; Orphan	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761083Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761083Orig1s000TOC.cfm

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
06/06/2022	SUPPL-15	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761083s015lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761083Orig1s015ltr.pdf
12/16/2021	SUPPL-13	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761083s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761083Orig1s013ltr.pdf
09/02/2021	SUPPL-11	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761083s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761083Orig1s011ltr.pdf
10/04/2018	SUPPL-4	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761083s002s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761083Orig1s002,761083Orig1s004Ltr.pdf
10/04/2018	SUPPL-2	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761083s002s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761083Orig1s002,761083Orig1s004Ltr.pdf

Labels for BLA 761083

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
06/06/2022	SUPPL-15	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761083s015lbl.pdf
12/16/2021	SUPPL-13	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761083s013lbl.pdf
12/16/2021	SUPPL-13	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761083s013lbl.pdf
09/02/2021	SUPPL-11	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761083s011lbl.pdf
10/04/2018	SUPPL-4	Efficacy-New Dosing Regimen	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761083s002s004lbl.pdf
10/04/2018	SUPPL-2	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761083s002s004lbl.pdf
11/16/2017	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf

Top